Neurotrope battered in latest Alzheimer's flop; Platelet BioGenesis raises $26M-plus
→ Neurotrope became the latest casualty in the high-risk Alzheimer’s R&D field. The biotech reported that their Phase II study of Bryostatin-1 failed to show any improvement over placebo using the Severe Impairment Battery (SIB) total score at week 13. In fact, the drug arm did a little worse than a sugar pill, with an average increase of 1.3 points for the drug and 2.1 points for placebo. Their shares $NTRP cratered in the rout that followed, plunging 78%. It’s currently a penny stock.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.